Dr. Basmah A. Jalil, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 19
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 164
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
MA license 290540
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cooley Dickinson Hospital Inc,the Northampton, MA
- Lakeland Hospital, St Joseph St Joseph, MI
Medical groups
- Lakeland Medical Practices (281 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 164
- Services billed
- 8,037
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Measurement c-reactive protein for detection of infection or inflammation | 335 | 170 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 328 | 169 |
| Insertion of needle into vein for collection of blood sample | 297 | 165 |
| Established patient office or other outpatient visit, 30-39 minutes | 294 | 140 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 146 | 75 |
| Liver function blood test panel | 143 | 79 |
| Blood creatinine level | 132 | 76 |
| Measurement of complement (immune system proteins), antigen, | 102 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 86 | 86 |
| Established patient office or other outpatient visit, 20-29 minutes | 82 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Bethesda, MD | 247 |
| Hydroxychloroquine Sulfate Other prescribers in Bethesda, MD | 124 |
| Leflunomide Other prescribers in Bethesda, MD | 105 |
| Methotrexate (methotrexate sodium) Other prescribers in Bethesda, MD | 91 |
| Allopurinol Other prescribers in Bethesda, MD | 55 |
| Duloxetine Hcl Other prescribers in Bethesda, MD | 42 |
| Cyclobenzaprine Hcl Other prescribers in Bethesda, MD | 41 |
| Xeljanz Xr (tofacitinib citrate) | 32 |
| Actemra Actpen (tocilizumab) | 29 |
| Rinvoq (upadacitinib) | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $1,239 in total to this clinician.
| Janssen Research & Development, LLC | $897 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $130 |
| UCB, Inc. | $125 |
| Biogen, Inc. | $35.00 |
| Madrigal Pharmaceuticals | $29.17 |
| Mallinckrodt Hospital Products Inc. | $23.64 |
| Travel and Lodging | $647 |
|---|---|
| Food and Beverage | $593 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Apr 8, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Janssen Research & Development, LLC Apr 8, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $154 |
| Janssen Research & Development, LLC Apr 9, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $142 |
| Janssen Research & Development, LLC Jun 5, 2025 | Travel and Lodging travel to HOUSTON, TX | $82.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $2,521,555 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
ModernaTX, Inc. · Completed · NCT05975099 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc. · Completed · NCT05831111 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis
Janssen Research & Development, LLC - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
ModernaTX, Inc. · Completed · NCT06060457
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.